The role of atorvastatin in bone metabolism in male albino Wistar rats

Pharmazie

Volumn 66, Issue 8, 2011, Pages 606-610

  Gradosova, Iveta ^a,b,c   Zivna, H ^a,b,c   Svejkovska, K ^a,b,c   Palicka, V ^a,b,c   Tichy, A ^a,b,c   Zivny, P ^a,b,c  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ATORVASTATIN; BONE MORPHOGENETIC PROTEIN 2; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PROCOLLAGEN C PROTEINASE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; COLLAGEN TYPE 1; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OSTEOPROTEGERIN; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N TERMINAL PEPTIDE; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMUR; FEMUR NECK; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; TIBIA; WESTERN BLOTTING; ANIMAL; BIOMECHANICS; BONE; DRUG EFFECT; METABOLISM; PHOTON ABSORPTIOMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PRENYLATION; WISTAR RAT;

ABSORPTIOMETRY, PHOTON; ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BIOMECHANICS; BLOTTING, WESTERN; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN TYPE I; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; OSTEOCALCIN; OSTEOPROTEGERIN; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROTEIN PRENYLATION; PYRROLES; RATS; RATS, WISTAR;

EID: 80053302438     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.1525     Document Type: Article

References (29)

1. Binkley N (2006) Osteoporosis in men. Arg Bras Endocrinol Metabol 50: 764-774.
2. Brown JP, Albert C, Nassar BA, Adachi JD, Cole D, Davison KS, Dooley KC, Don-Wauchope A, Douville P, Hanley DA, Jamal SA, Josse R, Kaiser S, Krahn J, Krause R, Kremer R, Lepage R, Letendre E, Morin S, Ooi DS, Papaioaonnou A, Ste-Marie LG (2009) Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem 42: 929-942.
3. Coxon FP, Rogers MJ (2003) The role of prenylated small GTP-binding proteins in the regulation of osteoclast function. Calcif Tissue Int 72: 80-84. (Pubitemid 36918941)
4. Garnero P, Vergnaud P, Hoyle N (2008) Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in post-menopausal osteoporosis. Clin Chem 54: 188-196. (Pubitemid 351182613)
5. Garrett IR, Mundy GR (2002) The role of statins as potential targets for bone formation. Arthritis Res 4: 237-240. (Pubitemid 34716303)
6. Hatzigeorgiou C, Jackson JL (2005) Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 16: 990-998. (Pubitemid 41127110)
7. Herrmann M, Seibel MJ (2008) The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: a comparative review. Clin Chim Acta 393: 57-75.
8. Jadhav SB, Jain GK (2006) Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 58: 3-18. (Pubitemid 43041991)
9. Lee AJ, Hodges S, Eastell R (2000) Measurement of osteocalcin. Ann Clin Biochem 37: 432-446. (Pubitemid 30426723)
10. Liao JK (2002) Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 86: 5-18.
11. Lieberman JR, Daluiski A, Einhorn TA (2002) The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 84-A: 1032-1044.
12. Maeda T, Kawane T, Horiuchi N (2003) Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 144: 681-692. (Pubitemid 36205242)
13. MajimaT, Komatsu Y, Fukao A, Ninomiya K, Matsumura T, Nakao K (2007) Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia. Endocr J 54: 145-151. (Pubitemid 46481683)
14. Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K (2008) Increased bone turnover in patients with hypercholesterolemia. Endocr J 55: 143-151. (Pubitemid 351520191)
15. Malhotra HS, Goa KL (2001) Atorvastatin: and updated review of its pharmacological properties and use in dyslipidaemia. Drugs 61: 1835-1881. (Pubitemid 32980510)
16. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S (2001) Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 21: 1636-1641. (Pubitemid 34215584)
17. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946-1949. (Pubitemid 129515901)
18. Parhami F, Garfinkel A, Demer LL (2000) Role of lipids in osteoporosis. Arterioscler Tromb Vasc Biol 20: 2346-2348.
19. Parhami F, Jackson SM, Tintut Y, Le V, Balucan JP, Teriito M, Demer LL (1999) Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J Bone Miner Res 14: 2067-2078. (Pubitemid 30026956)
20. Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L (2002) Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest 32: 581-589. (Pubitemid 36223410)
21. Rosenson RS, Tangney CC, Langman CB, Parker TS, Levine DM, Gordon BR (2005) Short-term reduction in bone markers with high-dose simvastatin. Osteoporos Int 16: 1272-1276. (Pubitemid 41396956)
22. Ruiz-Gaspa S, Nogues X, Enjuanes A, Monllau JC, Blanch J, Carreras R, Mellibovsky L, Grinberg D, Balcells S, Díez-Perez A, Pedro-Botet J (2007) Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem 101: 1430-1438. (Pubitemid 47242774)
23. Stern RH, Yang BB, Hounslow NJ, MacMahon M, Abel RB, Olson SC (2000) Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 40: 616-623.
24. TintutY, Morony S, DemerLL(2004) Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Tromb Vasc Biol 24: 6-10.
25. Tintut Y, Parhami F, Tsingotjidou A, Tetradis S, Territo M, Demer LL (2002) 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J Biol Chem 277: 14221-14226. (Pubitemid 34968036)
26. Turner CH, Burr DB (1993) Basic biomechanical measurements of bone: a tutorial. Bone 14: 595-608. (Pubitemid 23198821)
27. Uyar Y, Baytur Y, Inceboz U, Demir BC, Gumuser G, Ozbilgin K (2009) Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats. Maturitas 63: 261 - 267.
28. Viereck V, Gründker C, Blaschke S, Frosch KH, Schoppet M, Emons G, Hofbauer LC (2005) Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J Cell Biochem 96: 1244-1253. (Pubitemid 41681866)
29. Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA, Kucukazman M, Dal K, Hokkaomeroglu MS, Yavuz BB, Tutal E (2009) Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 23: 295-299.